- Home
- Publications
- Publication Search
- Publication Details
Title
Have we overestimated the benefit of human(ized) antibodies?
Authors
Keywords
-
Journal
mAbs
Volume 2, Issue 6, Pages 682-694
Publisher
Informa UK Limited
Online
2010-12-01
DOI
10.4161/mabs.2.6.13601
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α
- (2014) David J. Shealy et al. mAbs
- Natalizumab (Tysabri)
- (2010) D.T. Selewski et al. AMERICAN JOURNAL OF NEURORADIOLOGY
- Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM×anti-CD3) as a targeted cancer immunotherapy
- (2010) Diane Seimetz et al. CANCER TREATMENT REVIEWS
- Efficacy and Safety of Subcutaneous Omalizumab vs Placebo as Add-on Therapy to Corticosteroids for Children and Adults With Asthma
- (2010) Gustavo J. Rodrigo et al. CHEST
- U.S. Food and Drug Administration Approval: Ofatumumab for the Treatment of Patients with Chronic Lymphocytic Leukemia Refractory to Fludarabine and Alemtuzumab
- (2010) S. J. Lemery et al. CLINICAL CANCER RESEARCH
- Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma
- (2010) J. M. Kirkwood et al. CLINICAL CANCER RESEARCH
- A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody Directed Against EGFR in Patients with Advanced Solid Malignancies
- (2010) B. Kuenen et al. CLINICAL CANCER RESEARCH
- Continuous Therapy With Certolizumab Pegol Maintains Remission of Patients With Crohn's Disease for up to 18 Months
- (2010) Gary R. Lichtenstein et al. Clinical Gastroenterology and Hepatology
- Farletuzumab in epithelial ovarian carcinoma
- (2010) Whitney A Spannuth et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Immunotherapy of Type 1 Diabetes: Where Are We and Where Should We Be Going?
- (2010) Xunrong Luo et al. IMMUNITY
- Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
- (2010) William G. Wierda et al. JOURNAL OF CLINICAL ONCOLOGY
- High Rates of Durable Responses With Anti-CD22 Fractionated Radioimmunotherapy: Results of a Multicenter, Phase I/II Study in Non-Hodgkin's Lymphoma
- (2010) Franck Morschhauser et al. JOURNAL OF CLINICAL ONCOLOGY
- Report of a Multicenter Phase II Trial Testing a Combination of Biweekly Bevacizumab and Daily Erlotinib in Patients With Unresectable Biliary Cancer: A Phase II Consortium Study
- (2010) Sam J. Lubner et al. JOURNAL OF CLINICAL ONCOLOGY
- A Novel Strategy To Reduce the Immunogenicity of Biological Therapies
- (2010) J. Somerfield et al. JOURNAL OF IMMUNOLOGY
- Ustekinumab
- (2010) Oya Cingoz mAbs
- Structural and functional characterization of the trifunctional antibody catumaxomab
- (2010) Dirk Chelius et al. mAbs
- Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies
- (2010) Frank R. Brennan et al. mAbs
- Canakinumab
- (2010) Eugen Dhimolea mAbs
- The immunogenicity of humanized and fully human antibodies
- (2010) Fiona A. Harding et al. mAbs
- Development trends for human monoclonal antibody therapeutics
- (2010) Aaron L. Nelson et al. NATURE REVIEWS DRUG DISCOVERY
- Anti-p40 Antibodies Ustekinumab and Briakinumab: Blockade of Interleukin-12 and Interleukin-23 in the Treatment of Psoriasis
- (2010) Mona Gandhi et al. SEMINARS IN CUTANEOUS MEDICINE AND SURGERY
- Eculizumab
- (2009) Eline A. Dubois et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Ipilimumab: controversies in its development, utility and autoimmune adverse events
- (2009) Jeffrey Weber CANCER IMMUNOLOGY IMMUNOTHERAPY
- The Trifunctional Antibody Ertumaxomab Destroys Tumor Cells That Express Low Levels of Human Epidermal Growth Factor Receptor 2
- (2009) M. Jager et al. CANCER RESEARCH
- Phase I Study of Ipilimumab, an Anti-CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma
- (2009) S. M. Ansell et al. CLINICAL CANCER RESEARCH
- A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
- (2009) J. Weber et al. CLINICAL CANCER RESEARCH
- Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 years
- (2009) Kevan C. Herold et al. CLINICAL IMMUNOLOGY
- Safety Assessment and Dose Selection for First-in-Human Clinical Trials With Immunomodulatory Monoclonal Antibodies
- (2009) PY Muller et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies
- (2009) Patrick Y Muller et al. CURRENT OPINION IN BIOTECHNOLOGY
- Infections after the use of alemtuzumab in solid organ transplant recipients: a comparative study
- (2009) Nasia Safdar et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Current situation of zalutumumab
- (2009) Fernando Rivera et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Certolizumab pegol for the treatment of Crohn’s disease
- (2009) Danial E Baker Expert Review of Clinical Immunology
- Veto on vedolizumab (MLN0002) for Crohnʼs disease
- (2009) Daniel C. Baumgart INFLAMMATORY BOWEL DISEASES
- Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis†
- (2009) Daniel C. Baumgart et al. INFLAMMATORY BOWEL DISEASES
- Phase I Dose Escalation, Pharmacokinetic and Pharmacodynamic Study of Naptumomab Estafenatox Alone in Patients With Advanced Cancer and With Docetaxel in Patients With Advanced Non–Small-Cell Lung Cancer
- (2009) Hossein Borghaei et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Yttrium-90–Ibritumomab Tiuxetan in Patients With Relapsed or Refractory Mantle Cell Lymphoma
- (2009) Michael Wang et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment of Malignant Pleural Effusion With the Trifunctional Antibody Catumaxomab (Removab) (Anti-EpCAM×Anti-CD3)
- (2009) Martin Sebastian et al. JOURNAL OF IMMUNOTHERAPY
- The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti- 4 7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases
- (2009) D. Soler et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Safety, Pharmacokinetics, and Pharmacodynamics of the Insulin-Like Growth Factor Type 1 Receptor Inhibitor Figitumumab (CP-751,871) in Combination with Paclitaxel and Carboplatin
- (2009) Daniel D. Karp et al. Journal of Thoracic Oncology
- Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study
- (2009) David Olmos et al. LANCET ONCOLOGY
- Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome
- (2009) Helen J. Lachmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Raxibacumab for the Treatment of Inhalational Anthrax
- (2009) Thi-Sau Migone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo-controlled, dose-ranging study
- (2008) Mark C. Genovese et al. ARTHRITIS AND RHEUMATISM
- Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study
- (2008) Jonathan Kay et al. ARTHRITIS AND RHEUMATISM
- Molecular engineering and design of therapeutic antibodies
- (2008) Leonard G Presta CURRENT OPINION IN IMMUNOLOGY
- Zanolimumab, a human monoclonal antibody targeting CD4 in the treatment of mycosis fungoides and Sézary syndrome
- (2008) Dominik Sebastian Mestel et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Belimumab, an anti-BLyS human monoclonal antibody for potential treatment of inflammatory autoimmune diseases
- (2008) Changhai Ding EXPERT OPINION ON BIOLOGICAL THERAPY
- Novel therapies targeting the immune system: CTLA4 blockade with tremelimumab (CP-675,206), a fully human monoclonal antibody
- (2008) Luis H Camacho EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer
- (2008) Angèle L.M. Oei et al. INTERNATIONAL JOURNAL OF CANCER
- Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer
- (2008) Georgiana K. Ellis et al. JOURNAL OF CLINICAL ONCOLOGY
- Monoclonal Antibodies in Cancer Therapy: 25 Years of Progress
- (2008) Robert K. Oldham et al. JOURNAL OF CLINICAL ONCOLOGY
- Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus
- (2008) Richard Furie et al. ARTHRITIS RESEARCH & THERAPY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More